The impact of gabapentin administration on brain gaba and glutamate concentrations: A 7T 1H-MRS study

Neuropsychopharmacology

Volumn 37, Issue 13, 2012, Pages 2764-2771

  Cai, Kejia ^a   Nanga, Ravi P R ^a   Lamprou, Lisa ^b   Schinstine, Claudia ^b   Elliott, Mark ^a   Hariharan, Hari ^a   Reddy, Ravinder ^a   Epperson, C Neill ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

7 Tesla; g aminobutyric acid; GABA; gabapentin; Glu; glutamate

Indexed keywords

4 AMINOBUTYRIC ACID; GABAPENTIN; GLUTAMIC ACID;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BRAIN LEVEL; CLINICAL TRIAL; GLUTAMIC ACID BRAIN LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; VISUAL CORTEX;

ADMINISTRATION, ORAL; ADULT; AMINES; ANTICONVULSANTS; BRAIN; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; YOUNG ADULT;

EID: 84869088739     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.142     Document Type: Article

References (60)

1. Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000). Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47: 305-313.
2. Benedetti F, Calabrese G, Bernasconi A, Cadioli M, Colombo C, Dallaspezia S et al (2009). Spectroscopic correlates of antidepressant response to sleep deprivation and light therapy: a 3.0 Tesla study of bipolar depression. Psychiatry Res 173: 238-242.
3. Bielicki G, Chassain C, Renou JP, Farges MC, Vasson MP, Eschalier A et al (2004). Brain GABA editing by localized in vivo (1)H magnetic resonance spectroscopy. NMR Biomed 17: 60-68.
4. Cho SW, Cho EH, Choi SY (1998). Activation of two types of brain glutamate dehydrogenase isoproteins by gabapentin. FEBS Lett 426: 196-200.
5. Choi C, Ganji SK, DeBerardinis RJ, Dimitrov IE, Pascual JM, Bachoo R et al (2011). Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors. Magn Reson Med 66: 609-618.
6. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378: 1306-1315.
7. Cobas JC, Bernstein MA, Martin-Pastor M, Tahoces PG (2006). A new general-purpose fully automatic baseline-correction procedure for 1D and 2D NMR data. J Magn Reson 183: 145-151.
8. Dallocchio C, Buffa C, Mazzarello P, Chiroli S (2000). Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 20: 280-285.
9. Detre JA, Wang ZY, Bogdan AR, Gusnard DA, Bay CA, Bingham PM et al (1991). Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy. Ann Neurol 29: 218-221.
10. Edelsberg JS, Lord C, Oster G (2011). Systematic review and metaanalysis of efficacy, safety, and tolerability data from randomized controlled trials of drugs used to treat postherpetic neuralgia. Ann Pharmacother 45: 1483-1490.
11. Epperson CN, Gueorguieva R, Czarkowski KA, Stiklus S, Sellers E, Krystal JH et al (2006). Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl) 186: 425-433.
12. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W et al (2002). Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 59: 851-858.
13. Errante LD, Williamson A, Spencer DD, Petroff OA (2002). Gabapentin and vigabatrin increase GABA in the human neocortical slice. Epilepsy Res 49: 203-210.
14. Fink K, Meder W, Dooley DJ, Gothert M (2000). Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 130: 900-906.
15. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition. (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute: New York. November 2002.
16. Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN (1996). The novel anticonvulsant drug, gabapentin (Neurontin), binds to the a2d subunit of a calcium channel. J Biol Chem 271: 5768-5776.
17. Goa KL, Sorkin EM (1993). Gabapentin: A review of its pharmacological properties and clinical potential in epilepsy. Drugs 46: 409-427.
18. Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA et al (2001). Reductions in occipital cortex GABA levels inpanic disorder detected with 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 58: 556-561.
19. Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL (1995). Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 22: 1-11.
20. Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G et al (2011). Intravenous ethanol infusion decreases human cortical gamma-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 Tesla. Biol Psychiatry 71: 239-246.
21. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC (2008). Brain metabolism differs in Alzheimer's disease and Parkinson0s disease dementia. Alzheimers Dement 4: 421-427.
22. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC (2007). Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64: 193-200.
23. Hasler G, van der Veen JW, Geraci M, Shen J, Pine D, Drevets WC (2009). Prefrontal cortical gamma-aminobutyric acid levels in panic disorder determined by proton magnetic resonance spectroscopy. Biol Psychiatry 65: 273-275.
24. Heja L, Barabas P, Nyitrai G, Kekesi KA, Lasztoczi B, Toke O et al (2009). Glutamate uptake triggers transporter-mediated GABA release from astrocytes. PLoS One 4: e7153.
25. Honarmand A, Safavi M, Zare M (2011). Gabapentin: an update of its pharmacological properties and therapeutic use in epilepsy. J Res Med Sci 16: 1062-1069.
26. Kammerer M, Rassner MP, Freiman TM, Feuerstein TJ (2011). Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes. Naunyn Schmiedebergs Arch Pharmacol 384: 47-57.
27. Kassem MN, Bartha R (2003). Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4 Tesla incorporating macromolecule subtraction. Magn Reson Med 49: 918-927.
28. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X et al (2012). Elevated prefrontal cortex g-aminobutryic acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psych 69: 449-459.
29. Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E et al (2002). Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58: 368-372.
30. Leach JP, Sills GJ, Butler E, Forrest G, Thompson GG, Brodie MJ (1997). Neurochemical actions of gabapentin in mouse brain. Epilepsy Res 27: 175-180.
31. Licata SC, Renshaw PF (2010). Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction. Ann NY Acad Sci 1187: 148-171.
32. Loscher W, Honack D, Taylor CP (1991). Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neurosci Lett 128: 150-154.
33. Mader I, Seeger U, Karitzky J, Erb M, Schick F, Klose U (2002). Proton magnetic resonance spectroscopy with metabolite nulling reveals regional differences of macromolecules in normal human brain. J Magn Reson Imaging 16: 538-546.
34. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE (2011). Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull, e-pub ahead of print 11 July 2011.
35. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N et al (2001). Efficacy of gabapentin in migraine prophylaxis. Headache 41: 119-128.
36. Mathews GC, Diamond JS (2003). Neuronal glutamate uptake contributes to GABA synthesis and inhibitory synaptic strength. J Neurosci 23: 2040-2048.
37. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R (1998). Simultaneous in vivo spectral editing and water suppression. NMR Biomed 11: 266-272.
38. O'Gorman RL, Michels L, Edden RA, Murdoch JB, Martin E (2011). In vivo detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender effects. J Magn Reson Imaging 33: 1262-1267.
39. Petroff OA, Behar KL, Mattson RH, Rothman DL (1996a). Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. J Neurochem 67: 2399-2404.
40. Petroff OA, Hyder F, Mattson RH, Rothman DL (1999). Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 52: 473-478.
41. Petroff OA, Hyder F, Rothman DL, Mattson RH (2000). Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia 41: 675-680.
42. Petroff OA, Hyder F, Rothman DL, Mattson RH (2006). Brain homocarnosine and seizure control of patients taking gabapentin or topiramate. Epilepsia 47: 495-498.
43. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH (1996b). The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39: 95-99.
44. Petroff OA, Rothman DL, Behar KL, Mattson RH (1995). Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate, and glutamine in human brain. Epilepsia 36: 457-464.
45. Petroff OA, Rothman DL, Behar KL, Mattson RH (1996c). Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 46: 1459-1463.
46. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA et al (2009). Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 65: 792-800.
47. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
48. Rapchuk IL, O'Connell L, Liessmann CD, Cornelissen HR, Fraser JF (2010). Effect of gabapentin on pain after cardiac surgery: a randomised, double-blind, placebo-controlled trial. Anaesth Intensive Care 38: 445-451.
49. Rothman DL, Behar KL, Hetherington HP, Shulman RG. (1984). Homonuclear 1H double-resonance difference spectroscopy of the rat brain in vivo. Proc Natl Acad Sci USA 81: 6330-6334.
50. Rothman DL, Petroff OA, Behar KL, Mattson RH. (1993). Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA 90: 5662-5666.
51. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL et al (2004). Subtype-specific alterations of gammaaminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61: 705-713.
52. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA et al (1999). Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56: 1043-1047.
53. Sanacora G, Mason GF, Rothman DL, Krystal JH (2002). Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159: 663-665.
54. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7: 426-437.
55. Silverman RB, Adruszkiewicz R, Nanavati SM, Taylor CP, Vartanian MG (1991). 3-Alkyl-4 aminobutyric acids: the first class of anticonvulsant agent that activates L-glutamic acid decarboxylase. J Med Chem 34: 2295-2298.
56. Solinas M, Ferre S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR (2002). Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 22: 6321-6324.
57. Sutoo D, Akiyama K, Yabe K (2000). Quantitative maps of GAbAergic and glutamatergic neuronal systems in the human brain. Hum Brain Mapp 11: 93-103.
58. Taylor CP, Vartanian MG, Andruszkiewicz R, Silverman RB (1992). 3-Alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res 11: 103-110.
59. Terpstra M, Ugurbil K, Gruetter R (2002). Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7 Tesla. Magn Reson Med 47: 1009-1012.
60. Tkac I, Starcuk Z, Choi IY, Gruetter R (1999). In vivo 1H NMR spectroscopy of rat brain at 1ms echo time. Magn Reson Med 41: 649-656.